Under Miels, GSK has been looking to make deals in areas where the science is relatively settled. There is already a drug on the market — Merck & Co.’s Winrevair — that uses a similar mechanism to 35Pharma’s HS235. In addition to lowering blood pressure, it’s hoped that the experimental treatment will help preserve lean mass and reduce fat through weight loss.